Skip to main content

April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals

Payers' Guide, FDA Approvals
Zaltrap: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen
Lynne Lederman, PhD, Medical Writer
Read More
Payers' Guide, FDA Approvals
Zytiga Receives an Expanded Indication for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Zioptan Receives FDA Approval for Patients with Open-Angle Glaucoma and/or Ocular Hypertension
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Linzess: A Novel Treatment Option for Constipation Associated with Irritable Bowel Syndrome
Alice Goodman, Medical Writer
Read More
Payers' Guide, FDA Approvals
Perjeta: A New Option for Patients with HER2-Positive Metastatic Breast Cancer
Alice Goodman, Medical Writer
Read More
FDA Approvals, Payers' Guide
Trends in the 2013 Pharmaceutical Pipeline
Dalia Buffery, MA, ABD, Atheer A. Kaddis, PharmD
Read More
Payers' Guide, FDA Approvals
Iclusig: A New Treatment Option for Adults with CML or Ph+ ALL that Is Resistant/ Intolerant to Previous Therapy with TKIs
Lynne Lederman, PhD, Medical Writer
Read More
Payers' Guide, FDA Approvals
Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Rayos: A Novel Oral Delayed-Release Prednisone for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases
Alice Goodman, Medical Writer
Read More
Payers' Guide, FDA Approvals
Xeljanz: A New Treatment Option for Patients with Rheumatoid Arthritis
Alice Goodman, Medical Writer
Read More
Page 1 of 2
Results 1 - 10 of 20